Specifically, our study found that 11.4% (9/79) of COVID-19 infected women had liver biochemistry abnormalities upon admission, and 20% (8/40) of symptomatic women presented abnormal results, which were reflected through elevated levels of AST and ALT. This evidence concerns the gene GPT and COVID-19.